Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 942

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 942
---
 |

5. Intangible Assets Intangible assets consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

| ​                              | ​ | ​ | As ofSeptember 30,2024 |   |      |   | ​ | ​ | As ofDecember 31,2023 |   |      |   | ​ |
|:-------------------------------|:--|:--|:-----------------------|:--|-----:|:--|:--|:--|:----------------------|:--|-----:|:--|:--|
| Licensed patent rights         | ​ | ​ | ​                      | $ |  826 | ​ | ​ | ​ | ​                     | $ |  826 | ​ | ​ |
| Less: accumulated amortization | ​ | ​ | ​                      | ​ | -425 | ​ | ​ | ​ | ​                     | ​ | -378 | ​ | ​ |
| Total intangible assets, net   | ​ | ​ | ​                      | $ |  401 | ​ | ​ | ​ | ​                     | $ |  448 | ​ | ​ |

As of September 30, 2024, the expected remaining amortization expense is as follows (in thousands):

| Year Ended December 31, 
 Remainder of 2024       | ​ 
 ​ | ​ 
 ​ | Amount 
 ​      |   |  16 | ​ | ​ 
 ​ |
|:------------------------|:--|:--|:-------|:--|----:|:--|:--|
| 2025                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2026                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2027                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2028                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| Thereafter              | ​ | ​ | ​      | ​ | 133 | ​ | ​ |
| Total                   | ​ | ​ | ​      | $ | 401 | ​ | ​ |

The Company recognized less than $0.1 million for amortization expense for each of the nine months ended September 30, 2024 and 2023. Amortization expense is included in research and development expense in the statements of operations